Document:

Exhibit 10.5

Press Release

SOURCE: IGEN International, Inc.

IGEN Completes a $36.8 Million Equity Financing

GAITHERSBURG, Md., March 12 /PRNewswire-FirstCall/ -- IGEN International, Inc.
(Nasdaq: IGEN - news), announced today that it has completed a $36.8 million
private placement financing under which it sold a total of 1 million shares of
its common stock to Acqua Wellington Private Placement Fund, Ltd., and Acqua
Wellington Opportunity I Limited. Acqua Wellington targets investment
opportunities among mid-cap and small-cap publicly traded companies in domestic
and global markets with a primary focus in the technology and life science
sectors. Acqua Wellington states that its investment horizon is typically 12 to
24 months.

"This financing enhances our ability to continue advancing our business plans
and in particular our plan to commercialize the improvements to which we are
entitled from Roche Diagnostics under the recent final order of judgment issued
in our lawsuit against them," said Samuel J. Wohlstadter, Chairman & Chief
Executive Officer of IGEN International, Inc. "At minimal dilution, these
proceeds provide the Company with added financial resources, to complete the
transfer of improvements from Roche and to begin to commercialize products in
the $7 billion clinical immunodiagnostic market."

After IGEN's license to Roche Diagnostics, a division of F. Hoffmann- La Roche
(OTC Bulletin Board: RHHBY -news), is terminated IGEN will be free to use its
ORIGEN(R) technology and its extensive portfolio of patents, either
independently or with new partners, in the field currently licensed to Roche.
Even prior to termination of the license to Roche, which the company
anticipates will occur in the first half of 2003, IGEN is entitled to use its
ORIGEN technology and all Roche improvements, including the Elecsys 1010, 2010
and E170 lines of clinical diagnostic immunoassay analyzers and the tests
developed for use on those systems, for IGEN's retained field such as hospital
emergency rooms, intensive care units, physician office laboratories,
pharmaceutical research, life science applications and other settings. In
addition, the Company has an existing right to sell clinical diagnostic
instruments and tests developed by Eisai Co., Ltd., a multi-national
pharmaceutical and healthcare company, in all fields.

The Company plans to use the proceeds from this financing to advance its product
programs, including those programs associated with the transfer of the
improvements and products from Roche and Eisai and the exploitation of PCR for
DNA probe testing for clinical diagnostic and clinical research, to fund
research and development, provide working capital, and for general corporate
purposes. The Company may also use some of the proceeds to acquire or invest in
businesses, products or technologies complementary to its own.

The common shares issued by IGEN have not been registered under the Securities
Act of 1933, as amended, or any state securities or blue sky laws and may not
be offered or sold in the United States or in any state thereof absent

<PAGE>

registration or an applicable exemption from the registration requirements of
such laws. As part of this transaction, IGEN signed a registration rights
agreement under which it will register the shares of common stock issued. This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy common stock of IGEN.

IGEN develops and markets biological detection systems based on its
proprietary ORIGEN(R) technology, which provides a unique combination of
sensitivity, reliability, speed, and flexibility. ORIGEN-based systems are used
in a wide variety of applications, including clinical diagnostics,
pharmaceutical research and development, life science research, and industrial
testing for food safety and quality control. These systems are marketed by IGEN
and its licensees and/or distributors-Roche Diagnostics, Organon Teknika, Eisai
Co. Ltd., Sumitomo Corp., and Sanko Junyaku Co. Ltd. IGEN and ORIGEN are
registered trademarks of IGEN International Inc. Elecsys(R) is a registered
trademark of Roche. More information about the company can be found at
http://www.igen.com.

This release contains forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995, about litigation, including
the company's ability to maximize value of its technology, the company's
ability to use improvements in all fields, the prospects for establishing new
business arrangements with third parties, the delivery of improvements from
third parties, the value and utility of improvements to IGEN, the ability of
the company to commercialize products from other licensees, prospects for
developing new product offerings, the company's ability to compete in the
clinical diagnostics market, and prospects for ultimate success in the
litigation. Actual results might differ materially from these statements due to
risks and uncertainties, including decisions made by the court, decisions made
by Roche, ability to effectively transfer improvements, perceived value of the
improvements and ORIGEN technology to third parties, regulatory approval risks
and uncertainties, market factors, customer demands, among others. More complete
descriptions of the risks applicable to IGEN appear in the company's documents
filed with the Securities and Exchange Commission and available on request from
the company. IGEN disclaims any intent or obligation to update these
forward-looking statements.

SOURCE: IGEN International, Inc.Exhibit 10.13
FIRST AMENDMENT TO THE
AVON DEFERRED COMPENSATION PLAN

          THIS FIRST AMENDMENT is made on this 6th day of
December, 2001, by AVON PRODUCTS, INC., a corporation duly
organized and existing under the laws of the State of New York
(the "Company").

WITNESSETH:

          WHEREAS, the Company maintains the Avon Deferred
Compensation Plan (the "Plan"), as amended and restated effective
January 1, 1998;

          WHEREAS, the Company now desires to amend the Plan's
eligibility requirements; and

          WHEREAS, the Company now desires to change the type of
Annual Bonus an eligible employee may defer.

          NOW, THEREFORE, effective December 31, 2001, the
Company hereby amends the Plan as follows:

1. By deleting Section 1(a) in its entirety and by
substituting therefor the following:

"(a)	All or part of his or her annual cash bonus
awarded under the Company's Management Incentive Plan,
U.S. Incentive Plan or specified annual incentive
awards (collectively referred to as 'Annual Bonus');"

2.	By deleting Section 2 in its entirety and by
substituting therefor the following:

"2.	Eligibility:  Any employee of the Company may
participate in the Plan who is on the U.S. payroll,
eligible to participate in the Company's 1997 LTIP or
successor long term incentive plan, and selected by the
Company as eligible to participate in the Plan
(collectively referred to as 'Participants')."

Except as specifically amended hereby, the Plan shall
remain in full force and effect as prior to this First Amendment.

IN WITNESS WHEREOF, the Company has caused this First
Amendment to be executed on the date first written above.

                                    AVON PRODUCTS, INC.

                                    By:  /s/Andrea Jung

ATTEST: /s/Gilbert L. Klemann, II   Title: Chief Executive Officer
By:
Title:  SecretaryExhibit 10.19

Description of Consulting Arrangement with Fernando Lezama

Mr. Lezama will be retiring from the Company on March 31, 2002.  The
Company has arranged for Mr. Lezama to provide consulting services to the
Company relating principally to the Company's business in Latin America
and Asia Pacific for a period of up to two years after his retirement.  As
compensation for these consulting services, the Company will pay Mr.
Lezama during the consulting period a consulting fee equal to one-half of
Mr. Lezama's base salary at the time of his retirement.<PAGE>
Exhibit 10.21

                                FIRST AMENDMENT TO THE RESTATED
                             AVON PRODUCTS, INC. COMPENSATION PLAN
                                  FOR NON-EMPLOYEE DIRECTORS

The Avon Products, Inc. Compensation Plan for Non-Employee Directors (the
"Plan"), restated as of June 1, 2000 is hereby amended in accordance with
resolutions adopted by the Board of Directors of Avon Products, Inc. (the
"Company") on September 6, 2001.  The Plan is amended, effective January 1,
2002, as follows:

      1..Section 2.1 of the Plan is revised in its entirety to read as
         follows:

         "2.1  Annual Retainer  Each non-employee Director shall be entitled
         to receive an annual retainer consisting of (a)  $30,000 payable in
         cash and (b) an annual grant of Restricted Stock having a value as
         of the date of grant of approximately $30,000.  The cash portion
         shall be payable in quarterly installments of $7,500 each."

      2.  Section 3.1 of the Plan is revised in its entirety to read as
          follows:

          "3.1  Annual Grant of Stock Options  Each year a non-employee
          Director whose term of office is scheduled to continue beyond that
          year's Annual Meeting of Shareholders shall be granted a non-
          qualified option to purchase 4,000 shares of the Company's Common
          Stock.  Such grants shall coincide with the general annual grants
          of options to Company employees taking place during the first
          quarter of the year.  A non-employee Director who is first elected
          to the Board of Directors at an Annual Meeting of Shareholders,
          however, will receive his or her initial grant of options as of
          such date."

      Except as hereby amended, the Plan shall continue in full force and
      effect.

     IN WITNESS WHEREOF, the Company has caused this First Amendment of the
Plan to be executed as of this 6th day of September, 2001.

                                    AVON PRODUCTS, INC.

                                   By:  /s/ Andrea Jung
                                   Andrea Jung, Chief Executive Officer

ATTEST:

/s/ Gilbert L. Klemann II
Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]